LEXX News and Press, Lexaria Bioscience Corp. From 11/01/23

2023-11-01 08:30:58 ET NetworkNewsWire Editorial Coverage New York, NY – November 1, 2023 – GLP-1 agonists have become incredibly popular obesity drugs, reshaping the standard of care as people increasingly turn to the new class of drugs in lieu of conventional...

Lexaria, a global innovator in drug delivery platforms, just announced an exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology Lexaria will also perform specific DehydraTECH-related manufacturing operations on SulfoSyn’s behalf for an initial term of 2 yea...

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN ...

2023-10-30 08:30:25 ET NetworkNewsWire Editorial Coverage New York, NY – October 30, 2023 – The prestigious New England Journal of Medicine recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outco...

Lexaria has continuously taken steps to protect its intellectual property internationally to safeguard the applicability of its patented DehydraTECH(TM) technology across the globe The company recently announced that it had received two new Canadian patents, increasing to 37 the number of grant...

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform. The company continues to devote an increasing proportion of its resources and f...

Lexaria, a global innovator in drug delivery platforms, recently announced that it had entered into a securities purchase agreement with a single health-focused institutional investor The agreement is for the purchase of 1,618,330 shares of common stock at $0.97 per share, with gross proceeds a...

Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 20...

2023-10-13 10:17:20 ET More on Lexaria Bioscience Lexaria Bioscience enters into securities purchase agreement Seeking Alpha’s Quant Rating on Lexaria Bioscience Corp. Historical earnings data for Lexaria Bioscience Corp. Financial information for Lexa...

Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awarded Minimum ongoing payments, royalties and manufacturing revenues part of the agreement KELOWNA, BC / ACCESSWIRE / October 13, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXX...